Age-Dependent Anti-migraine Effects of Valproic Acid and Topiramate in Rats

Pokai Huang¹, Ping-Hung Kuo², Ming Tatt Lee³,⁴,⁵, Lih-Chu Chiou³,⁴,⁶ and Pi-Chuan Fan⁷*

¹ Department of Pediatrics, E-da Dachang Hospital, Kaohsiung, Taiwan, ² Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan, ³ Graduate Institute of Brain and Mind Sciences, College of Medicine, National Taiwan University, Taipei, Taiwan, ⁴ Graduate Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan, ⁵ Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur, Malaysia, ⁶ Graduate Institute of Acupuncture Science, China Medical University, Taichung, Taiwan, ⁷ Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan

Background: Valproic acid (VPA) and topiramate (TPM), initially developed as antiepileptics, are approved for migraine prophylaxis in adults but not children. The differences in their antimigraine mechanism(s) by age remain unclear.

Methods: A migraine model induced by intra-cisternal (i.c.) capsaicin instillation in pediatric (4–5 weeks) and adult (8–9 weeks) rats was pretreated with VPA (30, 100 mg/kg) or TPM (10, 30, 100 mg/kg). Noxious meningeal stimulation by the irritant capsaicin triggered trigeminovascular system (TGVS) activation mimicking migraine condition, which were assessed peripherally by the depletion of calcitonin gene-related peptide (CGRP) in sensory nerve fibers of the dura mater, the increased CGRP immunoreactivity at trigeminal ganglia (TG) and centrally by the number of c-Fos-immunoreactive (c-Fos-ir) neurons in the trigeminocervical complex (TCC). Peripherally, CGRP released from dural sensory nerve terminals of TG triggered pain signal transmission in the primary afferent of trigeminal nerve, which in turn caused central sensitization of the TGVS due to TCC activation and hence contributed to migraine.

Results: In the VPA-treated group, the central responsiveness expressed by reducing the number of c-Fos-ir neurons, which had been increased by i.c. capsaicin, was significant in pediatric, but not adult, rats. Inversely, VPA was effective in peripheral inhibition of elevated CGRP immunoreactivity in the TG and CGRP depletion in the dura mater of adult, but not pediatric, rats. In TPM group, the central responsiveness was significant in both adult and pediatric groups. Peripherally, TPM significantly inhibited capsaicin-induced CGRP expression of TG in adult, but not pediatric, rats. Interestingly, the capsaicin-induced depletion of CGRP in dura was significantly rescued by TPM at high doses in adults, but at low dose in pediatric group.

Conclusion: These results suggest VPA exerted peripheral inhibition in adult, but central suppression in pediatric migraine-rats. In contrast, TPM involves both central and peripheral inhibition of migraine with an optimal therapeutic window in both ages. These findings may clarify the age-dependent anti-migraine mechanism of VPA and TPM, which may guide the development of new pediatric anti-migraine drugs in the future.

Keywords: valproic acid, topiramate, age difference, migraine, CGRP
INTRODUCTION

As compared with adult migraine (12–17%) (Stewart et al., 1994; Wang, 2003), pediatric migraine is characterized by more bilateral involvement, shorter duration, less severity, better response to treatment (Swaiman et al., 1999), and lower prevalence (6–11%) (Abu-Arefeh and Russell, 1994; Wang et al., 2005). However, the mechanism(s) contributing to these differences remain unclear. The trigemino-vascular system (TGVS) consists of dural blood vessels which are innervated by unmyelinated small trigeminal afferent axons, trigeminal ganglia (TG), and the trigemino-cervical complex (TCC) (Liu-Chen et al., 1983; Mayberg et al., 1984; Uddman et al., 1985; Tsai et al., 1988; Nozaki et al., 1990). Peripheral sensitization of the TVGS via chemical stimulation may trigger migraine-like symptoms (Moskowitz, 1984, 1991). Central sensitization of the TGVS by TCC activation, which is involved in both nociceptive processing and cerebrovascular regulation, also plays a pivotal role in migraine pathophysiology (Lance et al., 1983). Activation of trigeminal nerves causes initial release of CGRP, which is regulated by antimigraine drugs (Durham and Russo, 1999). In a rat migraine model induced by intra-cisternal (i.c.) instillation of capsaicin, we have compared differences in central and peripheral responsiveness of the TGVS between pediatric and adult rats (Fan et al., 2012). We found that pediatric rats had a comparable central responsiveness, measured by the number of activated TCC neurons, as adult rats, but displayed less peripheral responsiveness than adults, including the CGRP immunoreactivity (CGRP-ir) in the TG and CGRP depletion (inversely reflected by CGRP-ir) in the dura mater (Fan et al., 2012).

Valproic acid (VPA) and topiramate (TPM), both clinically effective in migraine prophylaxis were used to validate this animal model. Both developed as antiepileptic drugs (AEDs), they are widely used to treat a number of non-epileptic pathologies, including headache prophylaxis, due to their neuronal stabilizing effects. The hypothesis of cortical hyperexcitability in migraine pathogenesis has led to a great number of large, randomized clinical trials to evaluate the efficacy and safety of AEDs in headache prevention (Colombo et al., 2008). However, it is not clear why only a few AEDs have a good efficacy in migraine prophylaxis. To stabilize the hyperexcitability in the cortex may not be the only mechanism for those effective epileptic drugs in migraine prophylaxis. The stabilization of TGVS activity, in terms of central and peripheral responses (Fan et al., 2012), by those AEDs may also play a role in their anti-migraine actions.

Among the AEDs, only VPA and TPM are approved by the Food and Drug Administration (FDA) for migraine prevention in adults and recently TPM was approved in pediatric migraine, but not VPA. However, their off-label use for pediatric migraine is a common practice. VPA is a GABA transaminase inhibitor and activator of glutamic acid decarboxylase, a GABA synthesizing enzyme (Chapman et al., 1982; Rogawski and Loscher, 2004). Thus, it can enhance GABAergic transmission, which may lead to the reduction of neurogenic inflammation response, contributing to its anti-migraine effect (Cutrer et al., 1997). However, its effect on the CGRP mediated response of TGVS has not yet been studied before. TPM has been demonstrated to modify several receptor- and voltage-gated ion channels, including Na\(^+\) channels, Ca\(^{2+}\) channels, and non-NMDA receptors, and GABA\(_A\) receptors which are involved in the initiation and propagation of seizure activity (White, 2005). Several animal studies have reported that TPM can reduce the TGVS activity.

MATERIALS AND METHODS

Animals

All animal care and experimental protocols were approved by the Institution of Care and Use of Laboratory Animals of the College of Medicine of National Taiwan University. The age for weaning in rats is P21 (3 weeks old), equal to 2 years in humans whereas sexual maturity is achieved after 7 weeks. Therefore, male Wistar rats at 8–9 weeks (275–300 g, adult group) and 4–5 weeks (101–125 g, pediatric group) were used. They were housed in an animal room with a 12-h light/12-h dark cycle and free access to food and water.

Intra-Cisternal Instillation of Capsaicin

The migraine model induced by i.c. instillation of capsaicin is similar to our previous study (Fan et al., 2012). Briefly, the rat received chloral hydrate (400 and 100 mg/kg, i.p., respectively, for inducing and maintaining) as anesthesia and catheterized with a catheter (PE-10, SIMS Portex Ltd, Hythe, United Kingdom) inserted 3 mm deep into the cisterna magna, followed by being placed in a prone position for 5.5 h. Rats received i.v. injection of VPA (Sanofi-Aventis, Paris, France) or its vehicle, or i.p. injection of TPM (Sigma-Aldrich, St. Louis, MO, United States) or its vehicle 30 min before capsaicin
administration. Then, the capsaicin solution (10 nmol, 100 µl) was instilled through the catheter into the cisterna magna over 1 min. The rat was then placed in a reverse Trendelenburg position (−30°) for 30 min in order to facilitate capsaicin distribution within the subarachnoid space, followed by a prone position for another 90 min. Capsaicin (Sigma Chemical, St. Louis, MO, United States) was dissolved in the vehicle solution containing 10% ethanol and 10% Tween 80, and sonicated for 5 min, and then further diluted (1:100) in artificial CSF as a stock solution stored at 4°C. For the sham control group, 100 µl of the vehicle was administered by i.c. instillation. Two hours after capsaicin instillation, the rat was euthanized by an overdose of chloral hydrate and then perfused via the ascending aorta with paraformaldehyde (4%) as described previously (Fan et al., 2012).

**Drug Administration of VPA and TPM**

VPA and TPM were administered at three doses in a 1X, 3X, 10X design applied in 4 animals in each of the groups with pretreatment. The doses of VPA (i.v.) injected was 30, 100, and 300 mg/kg (Cutrer et al., 1995b). However, the mortality rate was very high at 300 mg/kg. Thus, the results from the VPA groups at the doses of 30 and 100 mg/kg were demonstrated. TPM (i.p.) was instilled at the doses of 10, 30, and 100 mg/kg according to previous studies (Akerman and Goadsby, 2005a,b).

**TCC Brain Sections**

The brainstem with attached cervical cord was dissected, stored overnight, dehydrated and then were serially sectioned (50 µm) using a cryostat (LEICA CM3050S, Nussloch, Germany) from 1 mm rostral to the obex to the C6 level of the spinal cord. The sections at +0.6, −1.2, and −9 mm from the obex of adult and +0.6, −0.6, and −6 mm from the obex of pediatrics (Fan et al., 2012) were collected and subjected to c-Fos immunohistochemical staining. Four rats in each group were studied and the total number of c-Fos-immunoreactive (c-Fos-ir) TCC neurons was estimated based on the formula derived in our previous study (Fan et al., 2012).

**TG Slice Sections and Quantification**

The rat TG was dissected, stored overnight, embedded by paraffin wax and then serially sectioned at 5 µm thickness using a microtome (LEICA RM2245, Nussloch, Germany). Every third section was used for CGRP immunohistochemical staining, and we analyzed nine sections per ganglion in the TG. The ratio of positivity was defined as positive-stained area divided by total section area. The strength of immunoreactivity was measured by mean staining intensity subtracted from background using the software of image J. The CGRP-ir of TG was quantified as ratio of positivity multiplied by strength of immunoreactivity.

**Dura Mater Preparations and Quantification**

The dura mater dissected from the cranial cavity of the rat was prepared as described previously (Fan et al., 2012) for CGRP immunohistochemical staining. Four identical areas of fixed regions of the dura were selected and viewed under an inverted microscope (ZEISS Axio Observer.D1). The total lengths of positive-stained segmented lines in the field (100X) were measured in pixels by the software of image J. The CGRP density of dura was quantified and averaged as length (pixels) per field.

**Immunohistochemistry of c-Fos Protein in TCC Sections**

Free-floating immunohistochemistry of c-Fos protein was conducted using the avidin-biotin method as described previously (Fan et al., 2012), incubated with an anti-c-Fos rabbit polyclonal antibody (Calbiochem, San Diego, CA, United States) in 1:7000 dilution at 4°C for 48 h followed by incubation with biotinylated anti-rabbit IgG (Vector Labs, Burlingame, CA, United States) in 1:200 dilution for 2 h at room temperature and then incubated with horseradish peroxidase avidin D (Vector Labs, Burlingame, CA, United States) in 1:500 dilution for 1 h in the dark at room temperature. Immunoreactions were visualized using the DAB Reagent kit (KPL, Gaithersburg, MD, United States).

**Immunohistochemistry of CGRP in TG Slices and Dura Mater**

Immunohistochemical staining of CGRP was performed with the avidin-biotin method with a protocol similar to that for c-Fos staining except using a 30 min-blocking incubation, anti-CGRP rabbit polyclonal antibody (1:1000, Calbiochem, San Diego, CA, United States), and horseradish peroxidase avidin D (1:200 Vector Labs, Burlingame, CA, United States).

**Statistical Analysis**

All analysis was done using IBM SPSS Statistics 20 for Windows. Data were expressed as mean ± SE unless otherwise specified. Each treatment group was performed individually. Differences between the drug (VPA or TPM) treatment group and capsaicin only group were compared using the Mann–Whitney U-test. Statistical significance was a p-value < 0.05.

**RESULTS**

**VPA Reduced the Number of Capsaicin Induced c-Fos-ir TCC Neurons in Pediatric but Not Adult Rats**

After rats receiving i.c. capsaicin (10 nmol) instillation for 2 h, the number of c-Fos-ir TCC neurons was significantly increased in both adult (Figure 1A) and pediatric (Figure 1B) rats, as reported in our previous study (Fan et al., 2012). In the group pretreated with VPA at 100 mg/kg (i.v.), but not 30 mg/kg, the number of c-Fos-ir TCC neurons was decreased significantly in pediatric rats (p = 0.021) (Figure 1B), but not in adult rats at
Either 30 or 100 mg/kg (Figure 1A). This suggests that the central responsiveness, expressed by c-Fos-ir neurons in TCC, to VPA is only significant at a high dose in pediatric rats, but not in adult rats even at high does.

**VPA Reduced Elevated TG CGRP-ir and Dural CGRP Depletion in Adult but Not Pediatric Rats**

After i.c. capsaicin instillation, the CGRP-ir of TG was significantly increased in adult (p = 0.021) (Figure 1E) but not pediatric (Figure 1F) rats, as reported in our previous study (Fan et al., 2012). In the adult group pretreated with VPA (i.v.), the CGRP-ir of TG was significantly decreased at 100 mg/kg (p = 0.034) and borderline at 30 mg/kg (p = 0.05) (Figure 1E). VPA was effective in peripheral inhibition of CGRP expression in the TG of adult rats in a dose dependent way (Figure 1E).

After i.c. capsaicin instillation, the depletion of CGRP in dura was quantified by measuring CGRP-ir length in this study and was significant in both adult (p = 0.034) (Figure 1H) and pediatric (p = 0.021) (Figure 1I) rats. The depletion of CGRP was significantly reversed by VPA at 30 mg/kg (p = 0.034) and 100 mg/kg (p = 0.014) in adult group. I Capsaicin i.c. significantly depletes CGRP-ir in the dura of pediatric (p = 0.021). The rescue of CGRP depletion is not obvious at 30 (PCV30 vs. PC) and 100 mg/kg (PCV100 vs. PC) in pediatric group. *p < 0.05 by Mann–Whitney U-test, scale bar: 100 μm.

These results that VPA is effective in treating capsaicin induced nociception in both age groups validate this animal model. It suggests the anti-migraine mechanism of VPA involves
mainly peripheral inhibition of TGVS in adult rats, whereas central suppression of TCC in pediatrics. VPA at high dose, 100 mg/kg, is better than low dose, 30 mg/kg, in both central and peripheral responsiveness in this migraine model.

**TPM Reduced c-Fos-ir TCC Neurons in Both Age Groups**

Topiramate reduced the number of capsaicin induced c-Fos-ir TCC neurons at 30 and 100 mg/kg in both adult ($p = 0.043$ and 0.021, respectively) (Figures 2A,B) and pediatric ($p = 0.021$) (Figures 2A,C), but not at 10 mg/kg ($p > 0.05$) in both age groups (Figures 2B,C). The central responsiveness to TPM in both age groups is significant at the dose of 30 mg/kg or higher.

**TPM Reduced TG CGRP-ir in Adult and Rescued Dura CGRP Depletion in Both Age Groups**

Topiramate significantly reduced capsaicin-elevated CGRP-ir in TG at 10, 30, and 100 mg/kg ($p < 0.05$) in a dose-dependent way with a better response at a lower dose in adult rats (Figures 2D,E). However, TPM was ineffective in the pediatric group, possibly due to the null effect of capsaicin in TG CGRP expression in pediatric rats (Figures 2D,F). These results suggest that TPM is effective in peripheral inhibition of CGRP expression in TG with a better response at low dosage in adults (Figures 2D,E).

The capsaicin-induced depletion of dural CGRP was significantly rescued by TPM at 30 ($p = 0.021$) and 100 ($p = 0.021$), but not 10, mg/kg in the adult group (Figures 2G,H). In the pediatric group, the rescue of CGRP depletion is significant at 10 mg/kg ($p = 0.029$) and 30 ($p = 0.043$), but not obvious at 100 mg/kg ($p = 0.08$) (Figures 2G,I).

These results that TPM is effective in attenuating capsaicin-induced central and peripheral nociceptive responses in both age groups validate this animal model. It also suggests that the anti-migraine mechanism of TPM involves both central and peripheral inhibition of TGVS. A better response was observed at a high dose of TPM for the responsiveness at TCC and dura in contrast to a low dose for TG in adult rats. However, in the pediatric group, a better response was found at a high dose of TPM for the central responsiveness at TCC in contrast to a low dose for dura. The better responsiveness to TPM at a high dose centrally is similar in both age groups, but the trend of responsiveness is different peripherally in both ages. There may be a therapeutic window for a better response in both central and peripheral inhibition, such as 30 mg/kg in this model.

**DISCUSSION**

In this study, we found that VPA and TPM, two clinically effective antimigraine drugs, are effective in suppressing central (TCC) or peripheral (TGVS) migraine responses induced by capsaicin in both adult and pediatric rats. These results validate this animal model induced by *i.e.* capsaicin and reveal the age-dependent differences in the antimigraine mechanism of these two drugs. VPA suppressed c-Fos expression centrally, but not peripherally in the pediatric group, whereas induced peripheral, but not central, inhibition of the TGVS in adults. For TPM, the central suppression of c-Fos was significantly effective at higher dose (≥30 mg/kg) in both age groups. The peripheral inhibition of TGVS was significant in adults at the 3 doses in a dose-dependent way in contrast to pediatrics effective at a low dose. Interestingly, low-dose TPM is better than high-dose for peripheral suppression in adult TG and pediatric dura while high-dose TPM is better in central suppression at the TCC of both age groups. There may be an optimal therapeutic window for both central and peripheral inhibition, such as 30 mg/kg in this model. To the best of our knowledge, this is the first report to show the age differences in antimigraine mechanism of VPA and TPM.

**The Role of VPA in Migraine**

Intravenous VPA is clinically effective for abortive therapy of migraine headaches in adults and children (Kinze et al., 2001; Ashrafi et al., 2005). It has been studied and used for migraine prevention with success (Linde et al., 2013). VPA has been theorized to modulate GABA receptors and sodium/calcium neuronal channels that inhibit the excitatory process seen in migraine headaches (Cutrer et al., 1997). In the same capsaicin-induced migraine model in adult guinea pigs, VPA suppressed the elevated c-Fos expression in the trigeminal nucleus caudalis (TNC) (Cutrer et al., 1995a) in a manner mediated via GABA$_A$ receptors, but not GABA$_B$, receptors (Cutrer and Moskowitz, 1996). In the present study, we investigated capsaicin-induced elevation of c-Fos immunoreactive neuronal number in the TCC that includes TNC and upper cervical spinal cord, and the central suppression by VPA in adult rats is not significant. Different extension of investigation and different species may cause the difference. A recent transcriptomic profile study by Kogelman et al. (2018) revealed distinct transcriptomic profiles between TNC and spinal dorsal horn tissues in adult rats. Although the actual mechanism remains unknown, it may contribute to different responses in the TNC and the TCC (which includes the TNC and upper cervical spinal cord) toward the VPA treatment in *i.e.* capsaicin-induced migraine model. As for the age-dependent differences, a better central inhibition of TCC in the pediatric than adult might result from a switch in the subunit composition of GABA$_A$ receptor during postnatal development (Fritschy et al., 1994), suggesting that the existence of molecularly distinct immature and adult forms of GABA$_A$ receptors may differently respond to VPA.

Among neuropeptides, CGRP is the most widely spread and abundant (Skofitsch and Jacobowitz, 1985; Ishida-Yamamoto and Tohyama, 1989). This peptide was found in ranging from approximately 35% to almost 50% neurons of the TG in rats and man, present in small-sized cells previously (Lazarov, 2002). In capsaicin-treated rats, we found CGRP was densely distributed in TG neurons (Fan et al., 2018). In contrast to the inhibition of TNC neuronal activation via GABA$_A$ receptors, whether VPA treats migraine is mediated by CGRP remains unclear. VPA treatments had been shown to significantly reduce CGRP expression in dorsal root ganglia (DRG) and
improve the generalized hyperalgesia resulting from induced endometriosis (Zhao et al., 2011). This study with capsaicin-induced migraine model first provides direct evidence that VPA inhibited CGRP expression in TG and reversed CGRP depletion in dura. However, whether this CGRP depressant effect is secondary to its potentiation of GABA effect warrants further investigation. As for the null responsiveness in TG toward VPA in capsaicin-treated pediatric rats, it may be attributed to the postnatal development of TG neuron and its surrounding satellite glial cells (SGC). Glial-neuron interaction in the TG is crucial in regulating CGRP expression and release in relation to migraine pathogenesis (Thalakoti et al., 2007). Hayasaki et al. (2006) reported that both neurons and SGCs were stained immunopositive for GABA, and GABA would be released to inhibit CGRP activity in TG neuron. Interestingly, Durham and Garrett (2010) demonstrated that in rat TG, the number of glial cells associated with an individual neuron increased more than 3-folds from P0–P56. Thus, it is implicated that the density of SGCs, and thus GABA producing units in TG tissue in the pediatric group may be less than that in adults. This may explain the null peripheral responsiveness in pediatric rats toward VPA, which is an inhibitor of GABA transaminase that degrades GABA and an activator of glutamic acid decarboxylase, a GABA synthesizing enzyme (Chapman et al., 1982; Rogawski and Loscher, 2004).

**The Role of TPM in Migraine**

Topiramate is a neuromodulatory compound with stabilizing properties and has been demonstrated to modify several receptor-
and voltage-gated ion channels, including Na\(^+\) channels, Ca\(^{2+}\) channels, \(\alpha\)-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)/kainate receptors, and GABA\(_A\) receptors (White, 2005). The mechanism(s) of its antimigraine activity are unclear. We speculate that TPM might not inhibit c-Fos expression in TCC via GABA\(_A\) receptors in both ages because there are different trends between VPA and TPM in these two groups. It warrants further study to clarify the mechanism of central suppression by TPM in migraine.

In human, it was reported that intravenous administration of TPM attenuated the pain-related activity of parts of the thalamo-cortical network and increased functional coupling between the thalamus and several brain regions such as the bilateral precuneus, posterior cingulate cortex and secondary somatosensory cortex suggesting that TPM exhibits modulating effects on nociceptive processing in thalamo-cortical networks during trigeminal pain (Hebestreit and May, 2017). With the recent discovery of direct cortico-trigeminal inhibition from primary somatosensory cortex to TNC (Castro et al., 2017), and the existence of direct TNC innervation from secondary somatosensory cortex (Tashiro et al., 1983), it is speculated that TPM may activate that descending cortico-trigeminal inhibitory pathway, hence centrally suppressed the c-Fos expression in TCC of both pediatric and adult rats.

In the peripheral response, blocking peripheral GluR5 kainate receptors may contribute to its inhibition of neurogenic dorsal vasodilatation (Andreou et al., 2009). CGRP is involved in the anti-migraine mechanism of TPM that has been shown in many in vitro studies (Storer and Goadsby, 2004; Akerman and Goadsby, 2005a, b; Durham et al., 2006). Here, we demonstrated TPM attenuated CGRP expression and release in vivo. The exact mechanism how TPM regulates CGRP release remains to be elucidated. It is interesting to notice that in adult rats, there is a dose-dependent response with a better response at low doses of TPM in both peripheral effects, the suppression of TG CGRP and the rescue of dural CGRP depletion, but it had a better effect at higher doses in central suppressing TCC neuronal activation. These results suggest an optimal dose window of TPM for migraine therapy, namely 30 mg/kg in this study, which is compatible with the clinical experience (Brandes et al., 2004; Silberstein et al., 2004; Pringsheim et al., 2012). We hypothesize that at least dual mechanisms may contribute to the antimigraine effects of TPM in central and peripheral locations and the role of the mechanisms may be different at high and low doses, respectively. Therefore, further investigation of the role of GABA\(_A\) receptor, kainate receptor, and L-type calcium channel is required in the future.

CONCLUSION

In conclusion, both VPA and TPM are effective in central or/and peripheral suppression of capsaicin activation in both adult and pediatric rats. These results validate that this capsaicin-induced animal model can mimic migraine clinically. The antimigraine responsiveness to VPA and TPM are different in both pediatric and adult animals. VPA involved central suppression of TCC in the pediatric rat, in contrast to peripheral inhibition of TGVS in adult. TPM suppressed both central and peripheral responsiveness in both ages with an optimal therapeutic window. The exact mechanisms how c-Fos is suppressed by TPM and CGRP released is modulated by both drugs warrant further investigation. The current findings may shed light on the clinical observations of varied responsiveness in pediatric migraineurs toward the treatment with VPA (Bakola et al., 2009; El-Chammas et al., 2013) or TPM (Unalp et al., 2008; Le et al., 2017).

Limitation of the Study

The present study, for the first time demonstrates that VPA and TPM differentially exert their anti-migraine effect in pediatric and adult rat model of migraine induced by i.c. instillation of capsacin, via central and peripheral responses of TGVS. This in vivo model is a useful tool to study the histopathological changes in migraine-associated areas such as TG, the TCC and the dura mater, and has been employed to evaluate the pharmacological potency of various anti-migraine agents, including clinically effective VPA and a sumatriptan analog (Cutrer and Moskowitz, 1996; Cutrer et al., 1999). However, there are some limitations to the present model. First, in the present study the animals were under anesthesia throughout the study protocol. Further studies will have to be conducted to examine the effects of VPA and TPM in migraine-associated behaviors such as allodynia, facial grimace and photophobia (Harris et al., 2017). Second, only male rats were used in the present study. Further studies will be conducted to investigate the presence of sexual difference, with association with age-difference, in responsiveness toward migraine therapy.

AUTHOR CONTRIBUTIONS

PH and P-CF designed and conducted the experiments, analyzed the data, and wrote the paper. ML and LC-C contributed to data interpretation and paper writing. P-HK contributed to results discussion and paper writing.

FUNDING

This work was supported by the National Taiwan University Hospital (NTUH 101-M1999, NTUH102-M 2287, and NTUH 104-S2771); E- Da Hospital-National Taiwan University Hospital Joint Research Program (102-EDN10); the Ministry of Science and Technology, Taiwan (MOST-104-2923-B002-006-MY3), and National Health Research Institutes, Taiwan (NHRI-EX107-10733NI).

ACKNOWLEDGMENTS

The authors thank Mr. Tsu-Hsuan Lai and Ms. Hana Lin for their technical support.
REFERENCES

Abu-Arefeh, I., and Russell, G. (1994). Prevalence of headache and migraine in schoolchildren. BMJ 309, 765–769. doi: 10.1136/bmj.309.6957.765

Akerman, S., and Goadsby, P. J. (2005a). Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura. Neuroreport 16, 1383–1387.

Akerman, S., and Goadsby, P. J. (2005b). Topiramate inhibits trigeminovascular activation: an intravital microscopy study. Br. J. Pharmacol. 147, 7–14. doi: 10.1038/sj.bjp.0706290

Andreou, A. P., Holland, P. R., and Goadsby, P. J. (2009). Activation of iGluR5 kainate receptors inhibits neurogenic dorsal vasodilation in an animal model of trigeminovascular activation. Br. J. Pharmacol. 157, 464–473. doi: 10.1111/j.1476-5381.2009.01412.x

Ashrafi, M. R., Shabanian, R., Zamani, G. R., and Mahfelati, F. (2005). Sodium valproate versus propranolol in paediatric migraine prophylaxis. Eur. J. Paediatr. Neurol. 9, 333–338. doi: 10.1016/j.ejpn.2005.05.004

Bakola, E., Skapinakis, P., Tsoufi, M., Damigos, D., and Mavreas, V. (2009). Anticonvulsant drugs for pediatric migraine prevention: an evidence-based review. Eur. J. Pediatr. 173, 893–901. doi: 10.1007/s00431-008-0775-7

Brandes, J. L., Saper, J. R., Diamond, M., Couch, J. R., Lewis, D. W., Schmitt, J., Bakola, E., Skapinakis, P., Tzoufi, M., Damigos, D., and Mavreas, V. (2009). Calcitonin gene-related peptide (CGRP) and migraine. Eur. J. Neurosci. 14, 5302–5324. doi: 10.1111/j.1460-9568.2006.04832.x

Harris, H. M., Carpenter, J. M., Black, J. R., Smitherman, T. A., and Sufka, K. J. (2017). The effects of repeated nitroglycerin administrations in rats; modeling migraine-related endpoints and chronification. J. Neurosci. Methods. 284, 63–70. doi: 10.1016/j.jneumeth.2017.04.010

Hebestreit, J. M., and May, A. (2017). Topiramate modulates trigeminal pain processing in thalamo-cortical networks in humans after single dose administration. PLoS One 12:e0184406. doi: 10.1371/journal.pone.0184406

Ishida-Yamamoto, A., and Tohyama, M. (1989). Calcitonin gene-related peptide in the nervous tissue. Prog. Neurobiol. 33, 335–386. doi: 10.1016/0301-0082(89)90068-3

Kinze, S., Claus, M., Reuter, U., Wolf, T., Dreier, J. P., Einhaupl, K. M., et al. (2001). Valproic acid is effective in migraine prophylaxis at low serum levels; a prospective open-label study. Headache 41, 774–778. doi: 10.1046/j.1526-4610.2001.01142.x

Kogelman, L. J. A., Elgaard-Christensen, R., Olesen, J., Jansen-Olesen, I., and Hansen, T. F. (2018). Transcriptomic profiling of trigeminal nucleus caudalis and spinal cord dorsal horn. Brain Res. 1692, 23–33. doi: 10.1016/j.brainres.2018.04.037

Lance, J. W., Lambert, G. A., Goadsby, P. J., and Duckworth, J. W. (1983). Brainstem influences on the cephalic circulation: experimental data from cat and monkey with relevance to the mechanism of migraine. Headache 23, 258–265. doi: 10.1111/j.1526-4610.1983.hed2306258.x

Lazarov, N. E. (2002). Comparative analysis of the chemical neuroanatomy of the mammalian trigeminal ganglion and mesencephalic trigeminal nucleus. Prog. Neurobiol. 66, 19–59. doi: 10.1016/S0301-0082(01)00021-1

Le, K., Yu, D., Wang, J., Ali, A. I., and Guo, Y. (2017). Is topiramate effective for migraine prevention in patients less than 18 years of age? A meta-analysis of randomized controlled trials. J. Headache Pain 18:69. doi: 10.1186/s10194-017-0776-4

Linde, M., Mulleners, W. M., Chronicle, E. P., and McCrory, D. C. (2013). Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst. Rev. 6CD010611. doi: 10.1002/14651858.CD010611

Liu-Chen, L. Y., Mayberg, M. R., and Moskowitz, M. A. (1983). Different trigemino-vascular responsiveness between adolescent and adult rats in a migraine model. Cephalalgia 3, 298–302. doi: 10.1177/0331069X8300300205

Moskowitz, M. A. (1984). The neurobiology of vascular head pain. Neurology 34(2 Suppl. 2), S1–S59.

Nozaki, K., Uemura, Y., Okamoto, S., Kikuchi, H., and Mizuno, N. (1990). Origins of kainate receptors inhibiting neurogenic dural vasodilatation in an animal model. Headache 30, 765–769. doi: 10.1046/j.1526-4610.1990.90006-3

Rogawski, M. A., and Loscher, W. (2004). The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Can. J. Neurol. Sci. 31(2 Suppl. 2), S1–S59.

Silverstein, D. S., Neto, W., Schmitt, J., Jacobs, D., and Migri-001 Study Group. (2004). Topiramate in migraine prevention: results of a large controlled trial. Arch. Neurol. 61, 490–495. doi: 10.1001/archneur.61.4.490
Skofitsch, G., and Jacobowitz, D. M. (1985). Calcitonin gene-related peptide: detailed immunohistochemical distribution in the central nervous system. Peptides 6, 721–745. doi: 10.1016/0196-9781(85)90178-0

Stewart, W. F., Shechter, A., and Rasmussen, B. K. (1994). Migraine prevalence. A review of population-based studies. Neurology 44(6 Suppl. 4), S17–S23.

Storer, R. J., and Goadsby, P. J. (2004). Topiramate inhibits trigeminovascular neurons in the cat. Cephalalgia 24, 1049–1056. doi: 10.1111/j.1468-2982.2004.00767.x

Swaiman, K. F., Ashwal, S., and Ferriero, D. M. (1999). Pediatric Neurology: Principles and Practice, 5th Edn. Amsterdam: Saunders.

Tashiro, T., Matsuyama, T., and Higo, S. (1983). Distribution of cells of origin of the corticotrigenmal projections to the nucleus caudalis of the spinal trigeminal complex in the cat. A horseradish peroxidase (HRP) study. Exp. Neurol. 80, 178–185. doi: 10.1016/0014-4886(83)90014-6

Thalakoti, S., Patil, V. V., Damodaram, S., Vause, C. V., Langford, L. E., Freeman, S. E., et al. (2007). Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache 47, 1008–1023; discussion 1024–1005.

Tsai, S. H., Tew, J. M., McLean, J. H., and Shipley, M. T. (1988). Cerebral arterial innervation by nerve fibers containing calcitonin gene-related peptide (CGRP): I. Distribution and origin of CGRP perivascular innervation in the rat. J. Comp. Neurol. 271, 435–444. doi: 10.1002/cne.902710310

Uddman, R., Edvinsson, L., Ekman, R., Kingman, T., and McCulloch, J. (1985). Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci. Lett. 62, 131–136. doi: 10.1016/0304-3940(85)90296-4

Unalp, A., Uran, N., and Ozturk, A. (2008). Comparison of the effectiveness of topiramate and sodium valproate in pediatric migraine. J. Child Neurol. 23, 1377–1381. doi: 10.1177/0883073808318547

Wang, S. J. (2003). Epidemiology of migraine and other types of headache in Asia. Curr. Neurol. Neurosci. Rep. 3, 104–108. doi: 10.1007/s11910-003-0060-7

Wang, S. J., Fuh, J. L., Huang, K. D., and Lu, S. R. (2005). Rising prevalence of migraine in Taiwanese adolescents aged 13-15 years. Cephalalgia 25, 433–438. doi: 10.1111/j.1468-2982.2005.00873.x

White, H. S. (2005). Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache 45(Suppl. 1), S48–S56. doi: 10.1111/j.1526-4610.2005.4501006.x

Zhao, T., Liu, X., Zhen, X., and Guo, S. W. (2011). Levo-tetrahydropalmatine retards the growth of ectopic endometrial implants and alleviates generalized hyperalgesia in experimentally induced endometriosis in rats. Reprod. Sci. 18, 28–45. doi: 10.1177/1933719110381928

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.